News and Announcements
Dimerix’s Latest Research Validating the Relevance of DMX Receptor-HIT Technology Published in Scientific Reports Journal
- Published June 13, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company discovering and developing new therapeutic treatments identified using its proprietary assay technology today announce the publication of important research by Chief Scientific Advisor, Associate Professor Kevin Pfleger and colleagues in the leading peer reviewed journal Scientific Reports.
KEY TAKEAWAYS:
- Using state-of-the-art CRISPR technology, the team at the Harry Perkins Institute of Medical Research led by Associate Professor Pfleger has developed world first tools for studying functional receptor interactions in real time.
- Validate the relevance of the Dimerix Receptor-Heteromer Investigation Technology platform to monitor receptor complexes by labelling and monitoring endogenous receptors with tags for bioluminescence resonance energy transfer.
- The Receptor-HIT technology was used to identify DMX-200, Dimerix’s lead clinical stage drug development program, in Phase II of trials for the treatment of chronic kidney disease.
Associate Professor Pfleger highlighted that “This work has considerable potential for improving drug discovery and profiling, leveraging both Dimerix’s Receptor-HIT platform and the latest advances in genome editing”.
Dimerix’S CEO Kathy Harrison said: “Validation of the power of platform technologies which rely on analysis in vitro can be challenging. This pivotal piece of work has shown that the relevance of the heterodimers (the core premise of Receptor-HIT technology) can be demonstrated in cells in real time under endogenous promoter conditions, as occurs in the physiological setting.”
Company Updates
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Reinventing the Condom: How an Australian Deep-Tech Startup Plans to Disrupt a $12 Billion Market
For more than half a century, the global condom industry has remained fundamentally unchanged, constrained by standard materials like latex and solid synthetic polymers. Despite widespread consumer demand for better alternatives, product design has treated the device strictly as a mechanical barrier, sacrificing feel for function. Sydney-based Eudaemon Technologies is setting out to upend that […]
Backed By Leading Investment Groups and Family Offices
